Just a week after Cyclerion Therapeutics began trading on Wall Street, the spinoff from Cambridge’s Ironwood Pharmaceuticals has snagged a well-known drug industry executive as its chief innovation officer.
Andreas Busch, who led research and development at Shire and before that oversaw drug discovery for Bayer AG, is joining the company on Binney Street in Cambridge.
Peter Hecht, chief executive of Cyclerion, said he was thrilled to have recruited Busch to the startup, which is focusing on developing treatments for rare and life-threatening diseases.
“Andy is a terrific addition to our already deep and experienced leadership team,” Hecht said.
Busch spent 13 years at Bayer before joining Shire in January 2018. Busch has a deep background in the scientific approach that Cyclerion wants to use to treat rare disorders, including sickle cell disease, Hecht said.
Cyclerion has five drug development programs, including three of them in clinical trials. The company is focusing on the role that a “signaling molecule,” nitric oxide, plays in the human body in health and disease.
Busch said that Cyclerion has a “highly promising pipeline” and that joining the firm was a “once in a lifetime opportunity.”Jonathan Saltzman can be reached at firstname.lastname@example.org